India I Equities

Financials

Company Update

Change in Estimates ☑ Target ☑ Reco □

16 January 2023

Federal Bank

Strong guarter, RoEs to hold near current levels; maintaining a Buy

Higher margins and fee income led to a ~12% sequential increase in core operating profits for Federal Bank. The strong operating performance and benign credit cost (38bps) led to the better RoA. Asset quality was stable. Given the bank's strong liability franchise and capitalisation, it is set to gain market share in the near term. We maintain our positive view on it, with a Rs180 target price, valuing it at 1.3x P/ABV on its FY25e book.

RoE above 15% should be sustainable. A strong liability franchise combined with increased focus on a better yielding product mix would keep medium-term margins above 3.3%. Stable margins, strong fee income (high-teen credit growth) and benign credit costs should keep the bank's RoA near current levels in the medium term, translating to a 15%+ RoE for FY24/FY25.

Asset quality stable. Slippages for the quarter were Rs3.9bn (0.9% of loans), which were better than we expected. With most of the stress from the restructured book already recognized, the slippage run-rate is expected to hold near \sim 1% in the medium term. The coverage ratio also improved, by \sim 178bps, sequentially taking the PCR to \sim 69%.

Loan growth to be in high teens. The bank's loan book was Rs1.7tm (up \sim 19.5% y/y), driven by secular growth across segments. With very keen competition in the deposit market and moderating inflation levels, we expect overall credit growth for the bank to slightly moderate from current levels. We have factored in \sim 18% credit growth over FY24/FY25.

Valuation. Our Jan'24 sum-of-parts target price (1.3x FY25e book value, Rs10 a share for Fedfina and IDBI-Federal Life) works out to Rs180 a share. **Risk:** Lumpy slippages from the corporate book.

Key financials (YE Mar) (Rs m)	FY21	FY22	FY23e	FY24e	FY25e
Net interest income	55,337	59,620	71,743	84,652	99,518
Pre-provisioning profit	38,007	37,579	46,960	55,893	67,158
Provisions	16,634	12,218	8,685	10,327	12,527
PAT	15,903	18,898	28,630	34,084	40,864
EPS (Rs)	7.9	9.1	13.7	16.3	19.6
NIM (%)	3.2	3.1	3.3	3.3	3.3
Cost-Income (%)	49.3	53.3	49.9	49.1	47.9
RoE (%)	10.4	10.8	14.3	15.0	15.8
RoA (%)	0.8	0.9	1.2	1.2	1.3
Advances growth (%)	7.9	9.9	20.0	18.0	18.0
GNPA (%)	3.4	2.8	2.1	1.8	1.5
CAR (%)	14.6	15.8	14.1	13.8	13.6
P / E (x)	17.7	15.5	10.2	8.6	7.2
P / BV (x)	1.7	1.6	1.4	1.2	1.1
P / ABV (x)	1.9	1.6	1.4	1.3	1.1

Rating: **Buy**Target Price: Rs.180
Share Price: Rs.140

Key data	FB IN / FED.BO
52-week high / low	Rs.143 / 83
Sensex / Nifty	60093 / 17895
3-m average volume	\$23.6m
Market cap	Rs.297bn / \$3635.4m
Shares outstanding	2115m

Shareholding pattern (%)	Sep'22	Jun'22	Mar'22
Promoters	-	-	-
- of which, Pledged	-	-	-
Free float	100.0	100.0	100.0
- Foreign institutions	26.4	26.2	26.0
- Domestic institutions	44.3	42.1	43.3
- Public	29.4	31.7	30.7

Estimates revision (%)	FY24e	FY25e
Net interest income	(1.1)	(1.0)
Pre-provisioning profit	(2.5)	0.8
PAT	3.2	7.5



Source: Bloomberg

Yuvraj Choudhary, CFA Research Analyst

> Kaitav Shah, CFA Research Analyst

> > Sagar Rungta Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.


Anand Rathi Research India Equities


Quick Glance – Financials and Valuations

Fig 1 - Income state	Fig 1 – Income statement (Rs m)											
Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e							
Net interest income	55,337	59,620	71,743	84,652	99,518							
NII growth (%)	19.0	7.7	20.3	18.0	17.6							
Non-interest income	19,587	20,891	22,082	25,111	29,270							
Income	74,924	80,510	93,825	109,763	128,789							
Income growth (%)	13.9	7.5	16.5	17.0	17.3							
Operating expenses	36,917	42,932	46,865	53,870	61,631							
PPOP	38,007	37,579	46,960	55,893	67,158							
PPOP growth (%)	18.6	-1.1	25.0	19.0	20.2							
Provisions	16,634	12,218	8,685	10,327	12,527							
PBT	21,373	25,361	38,275	45,566	54,631							
Tax	5,470	6,463	9,645	11,483	13,767							
PAT	15,903	18,898	28,630	34,084	40,864							
PAT growth (%)	3.1	18.8	51.5	19.0	19.9							
FDEPS (Rs /sh)	7.9	9.1	13.7	16.3	19.6							
DPS (Rs /sh)	0.7	1.8	2.1	2.5	2.9							
Source: Company, Anand Rati	hi Research											

Fig 2 - Balance she	Fig 2 – Balance sheet (Rs m)											
Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e							
Share capital	3,992	4,205	4,230	4,230	4,230							
Reserves & surplus	157,252	183,733	208,069	237,040	271,774							
Deposits	1,726,445	1,817,006	2,107,727	2,487,118	2,934,799							
Borrowings	90,685	153,931	200,110	190,105	171,094							
	2,013,674	2,209,463	2,570,276	2,981,194	3,458,344							
Total liabilities												
	1,318,786	1,449,283	1,739,140	2,052,185	2,421,578							
Advances	371,862	391,795	462,318	517,796	579,931							
Investments	76,470	99,993	139,990	153,989	169,388							
Cash & bank bal	4,911	6,339	6,498	6,660	6,827							
Fixed & other assets	2,013,674	2,209,463	2,570,276	2,981,194	3,458,344							
Total assets	2,002	2,086	2,086	2,086	2,086							
No. of shares (m)	13.4	5.2	16.0	18.0	18.0							
Deposits growth (%)	7.9	9.9	20.0	18.0	18.0							
Advances growth (%)	3,992	4,205	4,230	4,230	4,230							
Source: Company, Anand Ra	athi Research											

Fig 3 - Ratio analysis	%				
Year-end: Mar	FY21	FY22	FY23e	FY24e	FY25e
NIM	3.2	3.1	3.3	3.3	3.3
Other inc. / total inc.	26.1	25.9	23.5	22.9	22.7
Cost-income	49.3	53.3	49.9	49.1	47.9
Provision coverage	63.6	63.9	69.1	68.7	69.6
Dividend payout	8.8	19.7	15.0	15.0	15.0
Credit-deposit	76.4	79.8	82.5	82.5	82.5
Investment-deposit	21.5	21.6	21.9	20.8	19.8
Gross NPA	3.4	2.8	2.1	1.8	1.5
Net NPA	1.2	1.0	0.7	0.6	0.5
BV (Rs)	80.6	90.1	101.8	115.7	132.3
Adj. BV (Rs)	75.1	85.4	97.9	111.7	128.5
CAR	14.6	15.8	14.1	13.8	13.6
- Tier 1	13.9	14.4	13.0	12.8	12.7
RoE	10.4	10.8	14.3	15.0	15.8
RoA	0.8	0.9	1.2	1.2	1.3
Source: Company, Anand Rathi	Research				







Key Highlights

Conference-call takeaways

FY23 guidance

- NIMs 3.35-3.4% (earlier 3.3%)
- Credit cost 50-55bps
- C/I ratio 48-49%
- RoA 1.25% (earlier 1.2%), 1.35% in FY24
- Branches 15 in Q4 FY23 (~175 in FY24 and FY25)

Repo-linked transmission

Loan book

- ~50% of the loan book is EBLR
- \sim 25% is the fixed rate.
- ~15% is MCLR


Quarterly snapshot


Fig 7 – GNPA												
(Rs m)	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23	Q3 FY23
Opening balance	36,187	35,308	36,556	35,522	34,702	46,024	46,493	44,458	44,013	41,367	41,553	40,311
Slippages	2,840	1,840	30	10,890	5,980	6,400	3,200	4,390	3,560	4,420	3,680	3,170
Retail	970	10	10	3,140	3,010	1,270	850	950	860	2,040	1,230	1,810
Agri	360	10	10	1,590	890	1,570	980	1,020	1,470	890	980	660
SME	1,220	80	10	3,040	2,080	2,860	1,370	1,920	1,230	1,490	1,470	640
Wholesale	290	1,740	-	3,120	-	700	-	500	-	-	-	60
Recovery	3,719	592	1,064	1,040	5,548	2,030	4,230	4,910	4,170	2,810	3,290	2,874
Closing balance	35,308	36,556	35,522	34,702	46,024	46,493	44,458	44,013	41,367	41,553	40,311	41,479
GNPA (%)	2.84	2.96	2.84	2.71	3.41	3.50	3.24	3.06	2.80	2.69	2.46	2.43
Gross slippage ratio (%)	0.92	0.60	0.01	3.40	1.77	1.94	0.94	1.22	0.96	1.15	0.90	0.74
Source: Company, Anand Rathi	Research											


Fig 8 – Loan book												
(%)	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23	Q3 FY23
Corporate (large & mid)	40.9	40.2	37.6	35.7	36.2	36.2	35.8	46.2	45.2	45.5	45.8	46.2
SME	18.3	18.1	18.9	19.2	18.7	17.9	18.6	8.4	8.5	8.3	8.3	8.3
Retail	30.5	30.7	31.6	32.9	33.3	33.1	32.5	31.8	32.4	32.3	32.0	31.5
Housing Loans	14.7	14.7	14.8	14.9	14.8	15.3	15.3	15.1	15.5	15.3	14.9	14.9
Mortgages	5.7	5.7	5.8	5.8	5.8	5.9	5.8	5.8	5.7	5.7	5.6	5.6
Others	10.1	10.3	11.1	12.2	12.6	8.3	8.4	8.0	8.1	8.0	8.2	8.3
Agriculture	10.4	11.0	11.9	12.2	11.9	12.8	13.1	12.8	13.0	12.9	12.9	12.9
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Source: Company, Anand Rath	ni Research											


Fig 9 - Income stat	ement											
(Rs m)	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23	Q3 FY23
Interest income	33,968	34,442	34,879	34,595	33,663	33,557	33,793	34,426	34,832	36,289	40,208	44,333
Interest expense	21,808	21,477	21,081	20,225	19,460	19,373	18,998	19,037	19,580	20,244	22,590	24,767
NII	12,160	12,964	13,799	14,370	14,204	14,184	14,794	15,389	15,252	16,045	17,618	19,565
Y/Y growth (%)	10.9	12.3	22.8	24.4	16.8	9.4	7.2	7.1	7.4	13.1	19.1	27.1
Non-interest income	7,111	4,884	4,494	4,754	4,775	6,483	4,917	4,842	4,650	4,526	6,095	5,340
Trading profits	3,690	3,040	-	1,060	590	2,950	880	470	40	250	800	60
Income	19,271	17,848	18,292	19,124	18,979	20,667	19,711	20,231	19,902	20,571	23,714	24,905
Y/Y growth (%)	27.8	15.5	18.4	22.4	(1.5)	15.8	7.8	5.8	4.9	(0.5)	20.3	23.1
Operating expenses	9,678	8,524	8,827	9,560	10,007	9,334	10,590	11,088	11,920	10,838	11,591	12,163
Of which, staff cost	5,191	4,959	4,875	5,256	5,252	5,283	5,719	5,831	6,373	4,993	5,156	5,608
PPOP	9,593	9,324	9,466	9,564	8,973	11,333	9,121	9,143	7,982	9,734	12,122	12,742
Y/Y growth (%)	27.1	19.1	31.7	28.6	(6.5)	21.5	(3.6)	(4.4)	(11.0)	(14.1)	32.9	39.4
Total provisions	5,675	3,946	5,321	4,142	2,545	6,399	2,926	2,140	752	1,667	2,679	1,987
PBT	3,918	5,378	4,145	5,423	6,428	4,934	6,195	7,003	7,230	8,067	9,444	10,755
Tax	906	1,370	1,069	1,382	1,650	1,261	1,592	1,786	1,824	2,060	2,407	2,719
PAT	3,012	4,008	3,076	4,041	4,778	3,673	4,603	5,217	5,405	6,007	7,037	8,036
Y/Y growth (%)	(21.0)	4.3	(26.2)	(8.3)	58.6	(8.4)	49.6	29.1	13.1	63.5	52.9	54.0
Source: Company, Anand Ra	thi Research											


Fig 10 - Balance She	eet											
(Rs m)	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22	Q1 FY23	Q2 FY23	Q3 FY23
Equity capital	3,985	3,990	3,989	3,990	3,992	3,990	4,203	4,200	4,205	4,210	4,219	4,230
Reserves & Surplus	141,191	145,240	148,363	152,460	157,244	160,890	173,067	178,320	183,733	189,720	193,269	201,650
Deposits	1,522,901	1,549,380	1,567,474	1,616,700	1,726,445	1,693,930	1,719,948	1,754,320	1,817,006	1,833,550	1,891,457	2,014,080
Borrowings	103,724	112,370	110,431	124,740	90,685	93,500	107,841	81,500	153,931	158,340	204,132	196,760
Other Liabilities	34,579	47,230	60,009	70,580	35,308	48,070	63,684	70,430	50,588	67,710	78,048	88,010
Equity and Liabilities	1,806,381	1,858,210	1,890,267	1,968,470	2,013,674	2,000,380	2,068,743	2,088,770	2,209,463	2,253,530	2,371,124	2,504,730
Deposits y/y growth %	12.8	16.9	12.3	11.8	13.4	9.3	9.7	8.5	5.2	8.2	10.0	14.8
Deposits q/q growth %	5.3	1.7	1.2	3.1	6.8	-1.9	1.5	2.0	3.6	0.9	3.2	6.5
Assets												
Cash and cash balances	61,749	58,870	61,199	64,100	76,470	82,840	84,856	95,260	99,993	131,570	126,543	139,670
Advances	1,222,679	1,212,970	1,229,120	1,255,050	1,318,786	1,297,650	1,344,046	1,407,430	1,449,283	1,516,890	1,612,403	1,681,730
Investments	358,927	347,490	362,526	343,890	371,862	373,910	369,767	374,950	391,795	411,860	435,713	462,650
Other Assets	99,029	98,340	102,135	115,780	127,112	128,930	135,024	153,250	158,282	165,150	173,070	181,550
Assets	1,806,381	1,858,210	1,890,267	1,968,470	2,013,674	2,000,380	2,068,743	2,088,770	2,209,463	2,253,520	2,371,124	2,504,720
Advances y/y growth %	10.9	8.3	6.1	5.3	7.9	7.0	9.4	12.1	9.9	16.9	20.0	19.5
Advances q/q growth %	2.6	-0.8	1.3	2.1	5.1	-1.6	3.6	4.7	3.0	4.7	6.3	4.3
Source: Company, Anand Rath	ni Research											
				· ·			· ·		· ·			














Valuation

■ Our Jan'24 sum-of-parts target price (1.3x FY25e book value, Rs10 a share for Fedfina and IDBI-Federal Life) works out to Rs180 a share.

Fig 17 – Change in estimates												
(Rs m)	Origin	al	Revise	ed	Change (%)							
	FY24e	FY25e	FY24e	FY25e	FY24e	FY25e						
Net interest income	85,564	100,528	84,652	99,518	(1.1)	(1.0)						
Pre-provisioning profit	56,901	66,204	55,502	66,709	(2.5)	0.8						
PAT	32,540	37,694	33,575	40,528	3.2	7.5						
Source: Anand Rathi Research												

Risks


- Lumpy delinquencies from the corporate loan book could harden our credit-cost estimates, manifesting in lower return ratios.
- Less-than-expected loan growth could distort our estimates.

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 16 January 2023)



			TP	Share
	Date	Rating	(Rs)	Price (Rs
18	22-Jan-18	Buy	127	102
19	10-May-18	Buy	104	90
20	17-Jul-18	Buy	112	88
21	16-Oct-18	Buy	105	82
22	4-May-19	Buy	115	98
23	16-Jul-19	Buy	130	107
24	16-Oct-19	Buy	95	82
25	20-Jan-20	Buy	110	94
26	29-May-20	Buy	55	43
27	15-Jul-20	Buy	58	50
28	19-Oct-20	Buy	60	50
29	21-Jan-21	Buy	90	77
30	17-May-21	Buy	96	82
31	25-Jul-21	Buy	100	85
32	24-Oct-21	Buy	120	104
33	14-Oct-22	Buy	150	130

Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps (<us\$1bn)< td=""><td>>25%</td><td>5-25%</td><td><5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd. (MCX-SX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No	

Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer Marco Polo Securities Inc. Transactions in securities discussed in this research report should be effected through Marco Polo Securities Inc.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2023. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.